Alnylam Pharmaceuticals Inc(ALNY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:54 PM ET (Korea 9/11 08:54)
Full metrics table
| Index | NDX | P/E | 41.79 | EPS (ttm) | 5.92 | Insider Own | 0.33% | Shs Outstand | 133.7M | Perf Week | -7.44% |
| Market Cap | 33.12B | Forward P/E | 24.56 | EPS next Y | 50.99% | Insider Trans | -1.72% | Shs Float | 133.4M | Perf Month | 11.89% |
| Enterprise Value | 32.80B | PEG | 0.33 | EPS next Q | 1.77 | Inst Own | 100.73% | Short Float | 3.58% | Perf Quarter | -15.01% |
| Income | 0.81B | P/S | 6.89 | EPS this Y | 186.44% | Inst Trans | -0.3% | Short Ratio | 2.62 | Perf Half Y | -22.76% |
| Sales | 4.80B | P/B | 24.44 | EPS next 5Y | 75.12% | ROA | 15.96% | Short Interest | 4.77M | Perf YTD | -37.76% |
| Book/sh | 10.13 | P/C | 10.01 | EPS past 3/5Y | - | ROE | 100.7% | 52W High | -50.05% ($495.55) | Perf Year | -47.26% |
| Cash/sh | 24.72 | P/FCF | 41.71 | Sales past 3/5Y | 52.98% 49.77% | ROIC | 20.01% | 52W Low | 25.13% ($197.81) | Perf 3Y | 22.88% |
| Dividend Est. | - | EV/EBITDA | 31.1 | EPS Y/Y TTM | 347.31% | Gross Margin | 79.65% | Volatility(W/M) | 5.44% 4.18% | Perf 5Y | 30.58% |
| Dividend TTM | - | EV/Sales | 6.83 | Sales Y/Y TTM | 95.14% | Oper. Margin | 20.81% | ATR (14) | 11.92 | Perf 10Y | 254.65% |
| Dividend Ex-Date | - | Quick Ratio | 2.99 | EPS Q/Q | 337.86% | Profit Margin | 16.82% | RSI (14) | 49.59 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.05 | Sales Q/Q | 66.86% | SMA20 | 1.93% ($242.82) | Beta | 0.26 | Target Price | $374.25 |
| Payout | - | Debt/Eq | 2.21 | Earnings | 2026/7/30 | SMA50 | -3.47% ($256.41) | Rel Volume | 0.85 | Prev Close | $258 |
| Employees | 2500 | LT Debt/Eq | 1.98 | EPS/Sales Surpr. | -25.78% -2.36% | SMA200 | -22.2% ($318.14) | Avg Volume(3M) | 1.82M | Price | $247.51 |
| IPO | 2004/5/28 | Option/Short | Yes/Yes | Trades | 27540 | Volume | 1,540,802 | Change | -4.07% |
Company
ALNY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A leading biotech company in RNAi (RNA interference)-based drug development. Founded in 2002 in Cambridge, Massachusetts, the company is headquartered in the United States and operates an RNAi therapeutics pipeline targeting rare genetic disorders, cardiovascular, central nervous system, and liver diseases. It stands as a flagship company within a leading biotech group in the RNAi therapeutics space.
Over the past 1 year, on the lower side
50% below its 1-year high.
ALNY makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +186.4% this year.
Tap to view numbers
But it is not cheap
Trading at 41.8 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +22.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 100.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.05%
EGGY 0.05%
EGGQ 0.05%
EGGS 0.04%
BBH 0.04%It ranks #4 in the industry
Based on market cap of $33B.
ALNY $33B PER 41.8
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ALNY?
ALNY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALNY?
The market cap of ALNY is approximately $33.1B, ranking 435 within its sector.
What is the P/E ratio of ALNY?
ALNY has a P/E ratio of approximately 41.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ALNY?
ALNY has recorded a 52-week high of $495.55 and a low of $197.81.
